GlassScriptPhysician profile
Jorge J Corona
NPI 1104816404
$3,277.25
in general payments reported to CMS, 2019-2025
14 companies · $971 in 2025
The $971 reported for 2025 was more than what 77% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
See the full distribution for Ophthalmic Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.32 · 2020: $256 · 2021: $469 · 2022: $1,023 · 2023: $310 · 2024: $233 · 2025: $971.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,514.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $944.33 | 2020-2023 | Tepezza |
| Eyevance Pharmaceuticals LLC | $693.24 | 2019-2023 | Flarex |
| Amgen INC. | $679.35 | 2024-2025 | Tepezza |
| Axogen | $420.17 | 2024-2025 | Axoguard Ha+ Nerve Protector, Axoguard Nerve Connector, Avance Nerve Graft |
| Merz Pharmaceuticals, LLC | $216.04 | 2022-2025 | Xeomin |
| Galderma Laboratories, L.P. | $71.85 | 2021-2022 | |
| Alcon Vision LLC | $51.93 | 2024 | Clareon |
| Abbvie INC. | $37.33 | 2022 | |
| Merz North America, INC. | $33.60 | 2020 | |
| Mallinckrodt Hospital Products INC. | $33.45 | 2020 | |
| Allergan, INC. | $28.96 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $23.76 | 2023 | |
| Genzyme Corporation | $22.28 | 2022 | |
| Sun Pharmaceutical Industries INC. | $20.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Corona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.